232 related articles for article (PubMed ID: 9456660)
1. Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-I.
Wahl SM; McNeely TB; Janoff EN; Shugars D; Worley P; Tucker C; Orenstein JM
Oral Dis; 1997 May; 3 Suppl 1():S64-9. PubMed ID: 9456660
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory function of secretory leukocyte proteinase inhibitor (SLPI) in human saliva is HIV-1 specific and varies with virus tropism.
Skott P; Lucht E; Ehnlund M; Björling E
Oral Dis; 2002 May; 8(3):160-7. PubMed ID: 12108760
[TBL] [Abstract][Full Text] [Related]
3. Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type I.
Shugars DC; Sauls DL; Weinberg JB
Oral Dis; 1997 May; 3 Suppl 1():S70-2. PubMed ID: 9456661
[TBL] [Abstract][Full Text] [Related]
4. Anatomic dissociation between HIV-1 and its endogenous inhibitor in mucosal tissues.
Wahl SM; Worley P; Jin W; McNeely TB; Eisenberg S; Fasching C; Orenstein JM; Janoff EN
Am J Pathol; 1997 Apr; 150(4):1275-84. PubMed ID: 9094984
[TBL] [Abstract][Full Text] [Related]
5. Endogenous salivary inhibitors of human immunodeficiency virus.
Shugars DC; Alexander AL; Fu K; Freel SA
Arch Oral Biol; 1999 Jun; 44(6):445-53. PubMed ID: 10401522
[TBL] [Abstract][Full Text] [Related]
6. Endogenous mucosal antiviral factors of the oral cavity.
Shugars DC
J Infect Dis; 1999 May; 179 Suppl 3():S431-5. PubMed ID: 10099113
[TBL] [Abstract][Full Text] [Related]
7. Secretory leukocyte protease inhibitor (SLPI): oxidation of SLPI does not explain its variable anti-HIV activity.
Konopka K; Shine N; Pretzer E; Düzgüneş N
J Dent Res; 1999 Dec; 78(12):1773-6. PubMed ID: 10598905
[TBL] [Abstract][Full Text] [Related]
8. Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk.
Farquhar C; VanCott TC; Mbori-Ngacha DA; Horani L; Bosire RK; Kreiss JK; Richardson BA; John-Stewart GC
J Infect Dis; 2002 Oct; 186(8):1173-6. PubMed ID: 12355371
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription.
McNeely TB; Shugars DC; Rosendahl M; Tucker C; Eisenberg SP; Wahl SM
Blood; 1997 Aug; 90(3):1141-9. PubMed ID: 9242546
[TBL] [Abstract][Full Text] [Related]
10. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro.
McNeely TB; Dealy M; Dripps DJ; Orenstein JM; Eisenberg SP; Wahl SM
J Clin Invest; 1995 Jul; 96(1):456-64. PubMed ID: 7615818
[TBL] [Abstract][Full Text] [Related]
11. The role of the oral environment in HIV-1 transmission.
Shugars DC; Wahl SM
J Am Dent Assoc; 1998 Jul; 129(7):851-8. PubMed ID: 9685760
[TBL] [Abstract][Full Text] [Related]
12. Human immunodeficiency virus type-1 (HIV-1) replication is unaffected by human secretory leukocyte protease inhibitor.
Turpin JA; Schaeffer CA; Bu M; Graham L; Buckheit RW; Clanton D; Rice WG
Antiviral Res; 1996 Mar; 29(2-3):269-77. PubMed ID: 8739605
[TBL] [Abstract][Full Text] [Related]
13. Oral transmission of HIV, reality or fiction? An update.
Campo J; Perea MA; del Romero J; Cano J; Hernando V; Bascones A
Oral Dis; 2006 May; 12(3):219-28. PubMed ID: 16700731
[TBL] [Abstract][Full Text] [Related]
14. Salivary secretory leukocyte protease inhibitor increases in HIV infection.
Lin AL; Johnson DA; Stephan KT; Yeh CK
J Oral Pathol Med; 2004 Aug; 33(7):410-6. PubMed ID: 15250833
[TBL] [Abstract][Full Text] [Related]
15. Expression of oral secretory leukocyte protease inhibitor in HIV-infected subjects with long-term use of antiretroviral therapy.
Nittayananta W; Kemapunmanus M; Yangngam S; Talungchit S; Sriplung H
J Oral Pathol Med; 2013 Mar; 42(3):208-15. PubMed ID: 23126266
[TBL] [Abstract][Full Text] [Related]
16. Enhanced secretory leukocyte protease inhibitor in human immunodeficiency virus type 1-infected patients.
Baqui AA; Meiller TF; Falkler WA
Clin Diagn Lab Immunol; 1999 Nov; 6(6):808-11. PubMed ID: 10548568
[TBL] [Abstract][Full Text] [Related]
17. Secretory leukocyte protease inhibitor and its potential interactions with elastase and cathepsin B in gingival crevicular fluid and saliva from patients with chronic periodontitis.
Cox SW; Rodriguez-Gonzalez EM; Booth V; Eley BM
J Periodontal Res; 2006 Oct; 41(5):477-85. PubMed ID: 16953825
[TBL] [Abstract][Full Text] [Related]
18. Differential mucosal susceptibility in HIV-1 transmission and infection.
Moutsopoulos NM; Greenwell-Wild T; Wahl SM
Adv Dent Res; 2006 Apr; 19(1):52-6. PubMed ID: 16672550
[TBL] [Abstract][Full Text] [Related]
19. Secretory leukocyte protease inhibitor: inhibition of human immunodeficiency virus-1 infection of monocytic THP-1 cells by a newly cloned protein.
Shine NR; Wang SC; Konopka K; Burks EA; Düzgüneş N; Whitman CP
Bioorg Chem; 2002 Aug; 30(4):249-63. PubMed ID: 12392704
[TBL] [Abstract][Full Text] [Related]
20. Salivary concentration of secretory leukocyte protease inhibitor, an antimicrobial protein, is decreased with advanced age.
Shugars DC; Watkins CA; Cowen HJ
Gerontology; 2001; 47(5):246-53. PubMed ID: 11490143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
